Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

NSAIDs: Electrolyte complications

Richard H Sterns, MD
Section Editor
Michael Emmett, MD
Deputy Editor
John P Forman, MD, MSc


Renal vasodilatory prostaglandins promote the secretion of renin, impair sodium reabsorption in the loop of Henle and cortical collecting tubule, and partially antagonize the ability of antidiuretic hormone (ADH) to increase water reabsorption in the collecting tubules [1-4]. Locally generated prostaglandins also may mediate part of the natriuretic effect of dopamine and of natriuretic peptides [5,6].

These actions are not of major importance in normal subjects in whom basal renal prostaglandin production is relatively low. However, they may become clinically significant when prostaglandin synthesis is stimulated by underlying renal disease or by the vasoconstrictors angiotensin II or norepinephrine. Secretion of these vasoconstrictors is increased in states of effective volume depletion: true volume depletion due to gastrointestinal or renal losses (as with diuretic therapy) or reduced tissue perfusion due to heart failure or cirrhosis.

In the setting of effective volume depletion, nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit prostaglandin synthesis, can produce a variety of complications related to renal dysfunction, each of which is reversible with discontinuation of therapy [1,2]. These include hyperkalemia, hyponatremia, and edema. These complications are mediated in part by reductions in the secretion of renin and aldosterone and by increased activity of ADH [1,2,7].

In addition, vasoconstriction due to decreased synthesis of vasodilator prostaglandins can impair renal function and exacerbate underlying hypertension and heart failure. These issues are discussed separately. (See "NSAIDs: Acute kidney injury (acute renal failure)" and "NSAIDs and acetaminophen: Effects on blood pressure and hypertension" and "Nonselective NSAIDs: Adverse cardiovascular effects", section on 'Patients with heart failure' and "COX-2 selective inhibitors: Adverse cardiovascular effects".)


Hyperkalemia — Nonsteroidal anti-inflammatory drugs (NSAIDs) have two effects that can promote the development of hyperkalemia: they lower renal renin secretion, which is normally mediated in part by locally produced prostaglandins [1,2,8]; and they impair angiotensin II-induced aldosterone release [8]. The ensuing fall in aldosterone secretion will reduce urinary potassium excretion, which will tend to raise the plasma potassium concentration.


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Sep 23, 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Oates JA, FitzGerald GA, Branch RA, et al. Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med 1988; 319:761.
  2. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993; 44:643.
  3. Kramer HJ, Glänzer K, Düsing R. Role of prostaglandins in the regulation of renal water excretion. Kidney Int 1981; 19:851.
  4. Hébert RL, Jacobson HR, Breyer MD. Prostaglandin E2 inhibits sodium transport in rabbit cortical collecting duct by increasing intracellular calcium. J Clin Invest 1991; 87:1992.
  5. Satoh T, Cohen HT, Katz AI. Intracellular signaling in the regulation of renal Na-K-ATPase. I. Role of cyclic AMP and phospholipase A2. J Clin Invest 1992; 89:1496.
  6. Gunning ME, Brady HR, Otuechere G, et al. Atrial natriuretic peptide(31-67) inhibits Na+ transport in rabbit inner medullary collecting duct cells. Role of prostaglandin E2. J Clin Invest 1992; 89:1411.
  7. Stichtenoth DO, Marhauer V, Tsikas D, et al. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. Kidney Int 2005; 68:2197.
  8. Campbell WB, Gomez-Sanchez CE, Adams BV, et al. Attenuation of angiotensin II- and III-induced aldosterone release by prostaglandin synthesis inhibitors. J Clin Invest 1979; 64:1552.
  9. Zimran A, Kramer M, Plaskin M, Hershko C. Incidence of hyperkalaemia induced by indomethacin in a hospital population. Br Med J (Clin Res Ed) 1985; 291:107.
  10. Walker RM, Brown RS, Stoff JS. Role of renal prostaglandins during antidiuresis and water diuresis in man. Kidney Int 1982; 21:365.
  11. Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. N Engl J Med 1984; 310:347.
  12. Clark BA, Shannon RP, Rosa RM, Epstein FH. Increased susceptibility to thiazide-induced hyponatremia in the elderly. J Am Soc Nephrol 1994; 5:1106.
  13. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310:563.
  14. Brater DC. Analysis of the effect of indomethacin on the response to furosemide in man: effect of dose of furosemide. J Pharmacol Exp Ther 1979; 210:386.
  15. Ng JL, Morgan DJ, Loh NK, et al. Life-threatening hypokalaemia associated with ibuprofen-induced renal tubular acidosis. Med J Aust 2011; 194:313.
  16. Page CB, Wilson PA, Foy A, et al. Life-threatening hypokalaemia associated with ibuprofen-induced renal tubular acidosis. Med J Aust 2011; 194:614.
  17. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69:1366.